Published in J Mol Cell Cardiol on January 15, 2010
Arginylation regulates myofibrils to maintain heart function and prevent dilated cardiomyopathy. J Mol Cell Cardiol (2012) 1.64
Thin filament mutations: developing an integrative approach to a complex disorder. Circ Res (2011) 1.55
Integration of troponin I phosphorylation with cardiac regulatory networks. Circ Res (2013) 1.38
Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. Proc Natl Acad Sci U S A (2011) 1.12
Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol (2016) 1.11
Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet (2012) 1.02
Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet (2014) 0.98
Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol (2011) 0.92
Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis. J Mol Cell Cardiol (2010) 0.86
Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy. J Biol Chem (2014) 0.86
Research priorities in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.86
Mechanistic heterogeneity in contractile properties of α-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies. J Biol Chem (2014) 0.81
N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2015) 0.80
Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil (2011) 0.79
Therapeutic Strategies Targeting Inherited Cardiomyopathies. Curr Heart Fail Rep (2017) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Cardiac excitation-contraction coupling. Nature (2002) 18.48
Hypertrophic cardiomyopathy: a systematic review. JAMA (2002) 9.15
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation (2003) 5.85
MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell (1997) 4.67
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med (2000) 4.30
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol (2005) 3.42
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (1998) 3.22
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation (1999) 3.19
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 2.68
Calcium cycling in congestive heart failure. J Mol Cell Cardiol (2002) 2.46
Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A (2000) 2.45
Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation (1999) 2.45
Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. Circ Res (2004) 2.44
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Hypertrophic cardiomyopathy. Lancet (2004) 2.41
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res (2003) 2.37
Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res (2000) 2.35
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23
Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation (2001) 2.22
Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet (1997) 2.20
Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 2.14
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther (2001) 2.13
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res (2007) 2.12
Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev (2005) 2.10
Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res (1995) 2.09
Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest (2008) 2.02
EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS. Circulation (1964) 1.96
Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol (2006) 1.95
Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest (1999) 1.95
Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest (1998) 1.94
Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet (2002) 1.93
Beta-adrenergic receptor stimulation increases unloaded shortening velocity of skinned single ventricular myocytes from rats. Circ Res (1994) 1.84
Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. Am J Physiol Heart Circ Physiol (2007) 1.84
Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol (2003) 1.84
Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol (2007) 1.82
Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res (1994) 1.81
Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res (2007) 1.80
The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun (2007) 1.77
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins. J Biol Chem (2008) 1.76
Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res (1998) 1.75
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol (2004) 1.72
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res (2007) 1.71
Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol (2007) 1.70
Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med (2004) 1.67
The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest (1998) 1.65
Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation (1999) 1.62
Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem (1998) 1.60
Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol (2007) 1.58
Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol (2000) 1.57
Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 1.55
Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res (1999) 1.55
Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev (2005) 1.54
A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J (2001) 1.53
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res (2007) 1.51
Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J Biol Chem (2000) 1.51
Dilated cardiomyopathy: a review. J Clin Pathol (2008) 1.50
Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res (2000) 1.49
Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci U S A (2002) 1.49
Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol (2002) 1.49
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil (2000) 1.44
Protein kinase D selectively targets cardiac troponin I and regulates myofilament Ca2+ sensitivity in ventricular myocytes. Circ Res (2007) 1.43
Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol (2009) 1.41
The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil (1997) 1.40
Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res (1999) 1.39
Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.38
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol (2001) 1.37
Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol (2001) 1.36
Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem (2000) 1.36
Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest (1996) 1.35
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol (1995) 1.33
Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest (2003) 1.33
Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol (1999) 1.32
Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1995) 1.32
Phospholamban and cardiac contractile function. J Mol Cell Cardiol (2000) 1.32
Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol (1998) 1.31
Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol (2008) 1.30
Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ Res (2007) 1.29
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A (2006) 1.29
Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol (1992) 1.29
Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res (1999) 1.28
Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation (1995) 1.26
Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail (2005) 1.26
Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol (2006) 1.25
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol (2011) 2.12
Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing. J Physiol (2003) 1.85
Roles of phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle twitch dynamics. J Physiol (2004) 1.40
Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ Res (2007) 1.29
Molecular and functional characterization of a novel cardiac-specific human tropomyosin isoform. Circulation (2010) 1.29
The effect of myosin regulatory light chain phosphorylation on the frequency-dependent regulation of cardiac function. J Mol Cell Cardiol (2006) 1.26
Expression of active p21-activated kinase-1 induces Ca2+ flux modification with altered regulatory protein phosphorylation in cardiac myocytes. Am J Physiol Cell Physiol (2008) 1.16
Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. J Mol Cell Cardiol (2011) 1.09
Chronic SR Ca2+-ATPase inhibition causes adaptive changes in cellular Ca2+ transport. Circ Res (2003) 1.07
Expression of slow skeletal troponin I in adult mouse heart helps to maintain the left ventricular systolic function during respiratory hypercapnia. Circ Res (2005) 1.03
alpha-Adrenergic response and myofilament activity in mouse hearts lacking PKC phosphorylation sites on cardiac TnI. Am J Physiol Heart Circ Physiol (2002) 1.01
Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2010) 0.97
Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K. J Cardiovasc Pharmacol (2015) 0.92
Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol (2011) 0.92
Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts. Cardiovasc Res (2004) 0.91
p21-activated kinase improves cardiac contractility during ischemia-reperfusion concomitant with changes in troponin-T and myosin light chain 2 phosphorylation. Am J Physiol Heart Circ Physiol (2011) 0.89
Arginine-glycine-aspartic acid (RGD)-containing peptides inhibit the force production of mouse papillary muscle bundles via alpha 5 beta 1 integrin. J Physiol (2005) 0.89
Correlations between alterations in length-dependent Ca2+ activation of cardiac myofilaments and the end-systolic pressure-volume relation. J Muscle Res Cell Motil (2008) 0.87
Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis. J Mol Cell Cardiol (2010) 0.86
Conserved Asp-137 is important for both structure and regulatory functions of cardiac α-tropomyosin (α-TM) in a novel transgenic mouse model expressing α-TM-D137L. J Biol Chem (2013) 0.84
Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy. J Biol Chem (2013) 0.83
Myofilament response to Ca2+ and Na+/H+ exchanger activity in sex hormone-related protection of cardiac myocytes from deactivation in hypercapnic acidosis. Am J Physiol Regul Integr Comp Physiol (2006) 0.82
Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension. Front Biosci (Elite Ed) (2010) 0.82
Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. J Biol Chem (2012) 0.81
Maintenance of adult cardiac function requires the chromatin factor Asxl2. J Mol Cell Cardiol (2012) 0.80
Calcineurin and cardiac function: is more or less better for the heart? Am J Physiol Heart Circ Physiol (2009) 0.80
Cardiac-specific expression of the tetracycline transactivator confers increased heart function and survival following ischemia reperfusion injury. PLoS One (2012) 0.79
Microarray analysis of active cardiac remodeling genes in a familial hypertrophic cardiomyopathy mouse model rescued by a phospholamban knockout. Physiol Genomics (2013) 0.78
Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation. Basic Res Cardiol (2014) 0.78
Differential effects of isoflurane and ketamine/inactin anesthesia on cAMP and cardiac function in FVB/N mice during basal state and beta-adrenergic stimulation. Basic Res Cardiol (2004) 0.78
Effects of nicotine administration in a mouse model of familial hypertrophic cardiomyopathy, α-tropomyosin D175N. Am J Physiol Heart Circ Physiol (2011) 0.78
Reversal of effects of acidosis on contraction of rat heart myocytes by CGP-48506. Front Biosci (2008) 0.75